The year in cardiovascular surgery  by Jones, Robert H
YT
R
D
T
s
b
2
c
i
s
s
w
e
v
Q
I
s
q
b
p
u
v
p
h
m
s
Y
g
m
F
h
p
m
l
C
e
c
t
u
C
h
o
t
s
Journal of the American College of Cardiology Vol. 43, No. 9, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2004.02.041EAR IN CARDIOLOGY SERIES
he Year in Cardiovascular Surgery
obert H. Jones, MD, FACC
urham, North Carolinao
C
t
r
v
f
o
t
c
O
v
m
h
p
1
c
P
a
m
q
a
d
r
i
d
y
1
a
p
m
p
C
r
i
p
t
N
t
p
f
i
r
s
p
ihis article highlights information from cardiovascular
urgery articles published in 2003 that are likely to have a
road impact on the practice of cardiovascular specialists in
004. A scan of major general and cardiovascular journals,
omplemented by a formal MEDLINE search, focused on
dentifying well-conducted randomized or observational
tudies of clinical outcomes that should guide cardiovascular
urgery care management decisions for individual patients
ith specific cardiovascular disease presentations. Prefer-
nce has been given to reporting articles that are fresh in
ision, thoughtful in design, and definitive in conclusions.
UALITY OF CARDIOVASCULAR SURGICAL CARE
nfluence of procedure volume on mortality. Table 1
ummarizes data from three separate studies that revisit the
uestion of whether surgeon and hospital coronary artery
ypass grafting (CABG) case volumes remain independent
redictors of mortality (1–3). All three large data sets that
sed different specific thresholds to define low and high
olumes of CABG by surgeons and hospitals suggest that
atients treated by low-volume surgeons at low-volume
ospitals may sustain as much as an additional 1.9%
ortality risk compared with those treated by high-volume
urgeons at high-volume institutions. Analysis of the New
ork State (NYS) data suggested that 125 cases per sur-
eons to be the optimal threshold of surgeon volume to
aintain quality without undue disruption of access to care.
or example, moving the 17,066 NYS patients from low- to
igh-volume surgeons and hospitals would be expected to
revent 106 patient deaths and decrease overall operative
ortality by 0.6%. This analysis suggests a potential regu-
atory approach to improving the outcomes of care of
ABG patients. However, a more appealing approach to
nsuring that patients receive the highest quality of CABG
are would be for all cardiac surgeons to voluntarily monitor
heir individual hospital risk-adjusted mortality statistics,
sing the Society of Thoracic Surgeons (STS) database.
Figure 1 depicts the relationship between risk-adjusted
ABG mortality and annual case volume for the 439
ospitals now using this approach to monitor CABG
utcomes. Annual hospital CABG volumes ranged from 39
o 1,754 (median 253, interquartile range 165 to 417), and
From the Department of Surgery/Duke Clinical Research Institute, Duke Univer-
ity Medical Center, Durham, North Carolina.Manuscript received February 17, 2004; accepted February 18, 2004.nly 18% of STS centers performed more than 500 isolated
ABG procedures per year. An association between hospi-
al volume and outcome persisted after adjusting for patient
isk and clustering effects (p 0.004). Moreover, the widest
ariance was observed among low-volume centers. There-
ore, it is especially important for cardiac surgeons who
perate at low- or medium-volume hospitals to prospec-
ively monitor and report risk-adjusted mortality to referring
ardiologists and patients, using standard methodology.
ther observations on the relationship between case
olume and patient outcome. Low-risk patients benefit as
uch or more than high-risk patients by receiving care at
igh-volume hospitals (4).
A study of MEDPAR data from 684 hospitals that
erformed more than 1.5 million heart operations between
994 and 1999 showed CABG hospital mortality rates
orrelated closely with mortality rates for valve surgery (5).
rovider profiling to improve CABG quality. Generation
nd publication of individual hospital and surgeon CABG
ortality rates, as a tool for public education and to guide
uality improvement initiatives, have been praised by some for
pparently lowering mortality rates and vilified by others for
iscouraging surgeons from appropriately intervening in high-
isk patients. To examine the influence of systematic monitor-
ng of quality on outcomes of cardiac surgery, administrative
ata in MEDPAR-Part A were analyzed for 911,407 65-
ear-old patients undergoing CABG in the U.S. during the
994 to 1999 period (6). A risk adjustment model derived from
dministrative data functioned with a c statistic of 0.71 in
redicting the risk of death and actual 30-day in-hospital
ortality rates. Except for New Jersey, all five regions with
rospective CABG mortality monitoring programs had lower
ABG mortality than the remainder of the U.S. For example,
isk-adjusted death in the hospital or within 30 days was 3.15
n 52,209 NYS patients, compared with 4.75 in 756,132
atients in U.S. regions without prospective mortality moni-
oring. There was no evidence of migration of patients out of
YS for CABG during this interval, which might suggest that
his program intimidated surgeons from accepting high-risk
atients. Over this entire time interval, the adjusted odds ratio
or all five regions with prospective CABG mortality monitor-
ng was 0.7 of the CABG mortality observed in all other
egions of the country. This magnitude of risk reduction
uggests that implementation of a national CABG reporting
rogram would prevent 1,800 needless CABG deaths annually
n this country.
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May 5, 2004:1706–14 Year in Cardiovascular Surgeryontinuous quality improvement intervention improves
ABG processes of care. Using the STS national cardiac
ata base, 359 academic and nonacademic hospitals treating
67,917 patients undergoing CABG between January 2000
nd July 2002 were randomized into a control arm or one of
wo groups that used continuous quality improvement
nterventions to increase the preoperative use of beta-
lockade and the incidence of internal mammary artery
IMA) grafting in elderly patients (7). After obtaining
aseline measurements at all sites, a sequence of three
ntervention rounds was begun in the two cohorts random-
zed to increased beta-blocker or IMA graft use by distri-
ution of materials to a local champion at these sites.
enters in the control arm received no interventional
aterial. All groups showed an increase in the two process
easures over time, but beta-blocker use was 7.3% more
ikely at sites receiving focused intervention on its appro-
riate preoperative use. Grafting of the IMA increased 8.7%
ore in elderly patients at IMA intervention sites, com-
ared with control sites. Although the magnitude of process
mprovement appeared modest, the use of professional
ociety resources to voluntarily conduct quality improve-
ent initiatives provides an important model worthy of
doption by other professional organizations.
URGERY FOR CORONARY ARTERY DISEASE (CAD)
omparison of CABG versus percutaneous coronary
ntervention (PCI). A meta-analysis of events occurring
p to eight years after randomization of 7,964 patients into
3 clinical trials compared outcomes of PCI and CABG
erformed during the 1987 to 1999 period (8). For all
able 1. Evidence for a Volume–Mortality Relationship of Coron
Data Source
(Collection/Quality)
CABG (Number and
Study Interval)
Vo
LV/HV Surge
ew York State
(prospective/audited)
57,150
1997–1999
125/125
ociety of Thoracic Surgeons
(prospective/voluntary)
267,089
2000–2001
86/139
EDPAR (retrospective/
administrative)
220,592
1998–1999
101/162
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CAD  coronary artery disease
IMA  internal mammary artery
LAD  left anterior descending coronary artery
MED  medical therapy
MR  mitral regurgitation
NYS  New York State
PCI  percutaneous coronary intervention
STS  Society of Thoracic Surgeons
SVR  surgical ventricular restorationABG  coronary artery bypass grafting; HV  high-volume; LV  low-volume.atients entered in all 13 trials, a 2% absolute survival
enefit favoring CABG was observed at five years but not at
arlier or later time intervals (Fig. 2). Trials enrolling only
atients with multivessel or proximal left anterior descend-
ng coronary artery (LAD) single-vessel CAD showed a
ignificant survival advantage of CABG over PCI-treated
atients at five years, which at eight years had increased to
3.4% absolute survival advantage. Patients with single-
essel proximal LAD disease experienced a 5.6% risk
eduction at five years for CABG compared with PCI. Data
rom four trials reporting subsets of diabetic patients
howed CABG provided an 8.6% survival advantage com-
ared with PCI at four years, but this difference became
nsignificant by 6.5 years. Repeat revascularization rates
ere lower with CABG compared with PCI, although
tents in more recent trials appeared to reduce the magni-
ude of this difference. In summary, these data show a
odest survival advantage of CABG over PCI in patients
ith multivessel disease. Longer term follow-up of more
ecent trials that treated patients with modern stenting may
essen this advantage. This meta-analysis of currently avail-
ble data provides a framework for assisting patients to
elect the most desirable form of revascularization for their
pecific clinical situation.
ecent CABG/PCI trial. A randomized comparison of
80 patients referred for PCI showed stenting to be more
ost effective than off-pump surgery at one year, while
aintaining comparable cardiac outcomes and quality of life
9).
n- and off-pump CABG comparison. A meta-analysis
f six studies, including 558 patients randomized to CABG
erformed on cardiopulmonary bypass and 532 randomized
o CABG without bypass, found no significant difference in
he combined end point of death, stroke, or myocardial
nfarction (10).
andomized comparison of primary CABG using the
adial artery or right internal thoracic artery or saphenous
ein as a randomly assigned conduit. A prospective,
andomized, single-center trial addressed the hypotheses
hat: 1) angiographic patency of the radial artery is superior
o that of the free right internal thoracic artery or saphenous
ein graft; and 2) patients who receive radial artery grafts
ould have superior outcomes to those who receive free
ight internal thoracic artery or saphenous vein grafts (11).
rtery Bypass Graft Surgery
Criteria Risk-Adjusted Mortality
(LV Surgeon and Hospital/
HV Surgeon and Hospital)
Mortality From
LVLV/HV Hospital
600/600 2.67/1.89 0.78
150/450 3.3/2.4 0.9
314/628 5.4/3.5 1.9ary A
lume
on
A
g
s
i
o
u
Figure 1. Each dot represents a hospital reporting data to the Society of Thoracic Surgeons National Cardiac Database. CABG  coronary artery bypass
grafting. Reprinted with permission from Peterson et al. (2), copyrighted © (2004), American Medical Association. All rights reserved.
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Year in Cardiovascular Surgery May 5, 2004:1706–14ll patients received an in situ left internal thoracic artery
raft to the LAD. The second graft utilized was assigned by
tratified randomization to be either a radial artery or rightoffman et al. (8) with permission from the American College of Cardiology.nternal thoracic artery in young patients or the radial artery
r saphenous vein in older patients. Saphenous veins were
sed for subsequent grafts, as needed. Between June 1996igure 2. Risk difference for all-cause mortality for years 1, 3, 5, and 8 after the initial revascularization. Event rates at years 1, 3, 5, and 8 were 3.0%, 4.7%,
.1%, and 13.7%, respectively, for all trials in the coronary artery bypass grafting (CABG) arm (A) and 3.4%, 5.3%, 8.9%, and 15.8% for the multivessel
oronary artery disease trials (B). The lines represent 95% confidence intervals. PTCA  percutaneous transluminal coronary angioplasty. Reprinted from
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May 5, 2004:1706–14 Year in Cardiovascular Surgerynd February 2002, 438 patients were enrolled: 285 assigned
o the younger group and 153 assigned to the older group.
o significant difference was seen in survival or cardiac
vent-free survival. Angiography was performed by random
ssignment at predetermined intervals between 0 and 10
ears. Five-year angiography was offered to all patients. The
ve-year patency rates were 95% for radial arteries and 100%
or right internal thoracic arteries in group 1. The five-year
atency rates were 87% for radial arteries and 94% for
aphenous veins in group 2. The five-year clinical and
ngiographic results of this study do not support the
ypothesis of greater patency or freedom from untoward
vents associated with radial artery conduit use.
onduit patency rates. The University of Melbourne
roup assessed patency in 1,402 CABG patients on 3,218
aphenous vein graft angiograms obtained between 1977
nd 1999 at a mean interval from CABG to repeat angio-
ram of 9.3 years and used multivariate analysis to identify
actors independently influencing graft patency (12). Grafts
ith 80% stenosis were considered patent. Table 2 sum-
arizes patient and operative variables found to be signifi- f
CABG  coronary artery bypass graft surgery.antly related to conduit patency at the level of 0.002.
ven after correction for the influence of the interval from
peration to angiography, the year of operation remained a
redictor of occlusion. The fact that grafts placed in 1990
ould be expected to have a 0.37 rate of occlusion, com-
ared with grafts performed in 1980, over comparable
ntervals to angiography, illustrates the fallacy of comparing
ld saphenous vein patency information to more recently
valuated arterial conduits. Younger age predicts worse graft
atency, as other causes of death remove older patients from
he study population at a greater rate, before graft occlusion
ecomes apparent. Greater blood flow through conduits
eading to the LAD or to large arteries results in lower
onduit occlusion. Because arterial grafts are commonly used
referentially for bypassing the LAD and other coronary
rteries with high blood flow, confounding can always be
xpected in comparisons of arterial and venous grafts. Lower
ow velocity in saphenous vein conduits with larger diameters
ppears to be the factor leading to higher occlusion of these
uboptimal vessels. Knowledge of these factors leads to the
roper interpretation of modern reports on conduit patencyTable 2. Independent Predictors of Saphenous Vein Graft Occlusion
Baseline Comparison OR 95% CI p Value
Patient variables
Year of operation x x  10 0.37 0.27–0.51 0.001
Age (yrs) x x  10 0.76 0.68–0.86 0.001
Interval between operation and
angiogram (yrs)
x x  10 1.68 1.28–2.21 0.001
Operative variables
Target artery LAD Diagonal 1.29 0.99–1.68 0.002
Marginal 1.39 1.11–1.75
Right 1.63 1.22–2.17
PDA or LV branch 1.34 1.03–1.74
Target artery diameter (mm) 0–0.9 1.0–1.4 1.59 0.44–5.79 0.001
1.5–1.9 0.93 0.26–3.35
2.0–2.4 0.78 0.22–2.82
2.5–3.4 0.61 0.16–2.30
Endarterectomy 1.69 0.27–10.50
Conduit diameter (mm) 1.5–2.4 2.5–3.4 1.09 0.43–2.77 0.001
3.5–4.4 1.62 0.64–4.11
4.5–5.4 2.17 0.83–5.67
5.5 2.36 0.77–7.16
CI  confidence interval; LAD  left anterior descending coronary artery; LV  left ventricular; OR  odds ratio; PDA rom small groups of patients followed for brief intervals.able 3. Graft Patency Over Time in 1,408 Symptomatic Patients
Conduit
Number of
Conduits
Mean
Years of
Follow-up
Interval in Years Between CABG and Angiogram
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Patients (%) With Angiographic Patency and and <80% Stenosis
aphenous vein 3,714 8.7 95 62 61 32
eft internal thoracic artery 1,345 6.6 98 96 95 88
ight internal thoracic artery 605 6.8 96 88 81 65
adial artery 177 2.2 96 89 89
ll arterial grafts 2,127 6.4 94
dapted from Tatoulis et al. (13).
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Year in Cardiovascular Surgery May 5, 2004:1706–14The University of Melbourne group also prospectively as-
essed conduit patency in 1,408 symptomatic patients after
ABG (13). Data tabulated for each type of conduit evaluated
ver time reflect surprisingly high patency rates, even in these
ymptomatic patients (Table 3). This information is useful to
ddress patient issues regarding optimal conduit use in discus-
ion before the anticipated CABG operation.
hock and CABG. A consecutive series of 259 patients
ndergoing CABG while in cardiogenic shock or receiving
ardiopulmonary resuscitation between 1979 and 2001 were
tudied using time-related and multivariate methodologies
14). Survival was 59% at 1 year and 47% at 10 years. A
ubstantial early hazard was followed by a normal hazard of late
eath. On multivariate analysis, comorbidity, treated diabetes,
lower pH at initiation of the operation, and the presence of
hree-vessel disease were independent predictors of lower
urvival. Advanced age contributed little, but most of the
opulation was young. The discriminating power for predic-
ion of hospital mortality using combinations of these variables
as low.
Data from the SHould we emergently revascularize Oc-
luded Coronaries for cardiogenic shocK? (SHOCK) trial
egistry now raise questions about the applicability of previ-
usly reported results in the prespecified75-year-old patient
ubgroup of the randomized cohort, which suggested that
ABG had no survival benefit (15) (Fig. 3). During the time
hese 56 patients were being randomized into the SHOCK
igure 3. Covariate relative risk and 95% confidence intervals for in-hosp
oronaries for cardiogenic shocK?) Registry patients who underwent early
tratified by age group. *Forty-five patients who died 3 h from admission
p 0.047] and previous CABG [p 0.017]). **Twenty patients who died
or transfer status [p  0.002] and inferior myocardial infarction locatio
ermission from the European Society of Cardiology.rial, 277 patients (age 75 years) were enrolled into the tHOCK registry. According to the SHOCK registry, elderly
atients who underwent early revascularization had a lower
ovariate-adjusted mortality than those who had revasculariza-
ion late or never. Characteristics of elderly patients that
uggested a better outcome with revascularization may have led
hysicians to select the registry in preference to randomization.
his registry finding raises the question of the generalizability
f the lack of benefit observed in the randomized cohort.
dvanced age should not be a categorical reason to deny
ABG to patients in shock.
ombined carotid artery endarterectomy and CABG. A
eview of 10,561 carotid endarterectomy reports from
edicare patients in 10 states identified 226 procedures
erformed in combination with CABG (16). Complete
edical records also were reviewed in 184 of these patients.
recent stroke or transient ischemic attack was the indi-
ation for carotid endarterectomy in only 12% of these
atients, and 56% of these patients were not symptomatic
rom their carotid disease. Procedure-related mortality was
.6%, and the combined end point of stroke and death was
7.7%. Moreover, 80% of nonfatal strokes were disabling.
hese community-based results of combined CABG and
arotid endarterectomy, which reflect a 15% incidence of
eath or disability, suggest that use of combined carotid
ndarterectomy and CABG is more widespread than is
ustified, especially in this population with a high represen-
ortality of the SHOCK (SHould we emergently revascularize Occluded
cularization (18 h after shock onset) versus late or no revascularization,
2 patients with missing baseline data were excluded (adjusted for diabetes
from admission and 28 patients with missing data were excluded (adjusted
 0.089]). ***See reference 10. Reprinted from Dzavik et al. (15) withital m
revas
and 1
3 h
n [pation of asymptomatic carotid disease.
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May 5, 2004:1706–14 Year in Cardiovascular SurgeryURGERY FOR VALVULAR HEART DISEASE
itral regurgitation (MR) management in patients un-
ergoing CABG. The management of mild to moderate
R in patients undergoing CABG remains controversial.
ncreasingly, outcomes are being reported on patients
rouped by the operation done and not by an objective
ssessment of MR severity. Because mitral valve operations
hat might be considered questionably indicated occur in
atients with less severe MR, the decision to perform a
itral valve operation immediately shifts one of the sickest
f the CABG-only patient cohorts to a position as one of
he least sickest members of the CABG/mitral surgery
ohort. Therefore, a low threshold for performing mitral
urgery during CABG improves mortality in both the
ABG-only and CABG/mitral surgery subgroups if the
ubgroups are defined by operation performed and not by a
easurement of disease severity.
A prospective study of 1,939 consecutive CABG patients
ncluded 167 patients in whom preoperative and intraoper-
tive echocardiograms objectively defined the presence of
ild to moderate MR, for whom some surgeons might add
itral valve surgery to CABG but for whom CABG
ithout mitral valve surgery was performed (17). These
atients with MR had an observed 11% decrement in 5-year
urvival and an 18% decrement in 10-year survival, com-
ared with patients without MR. However, after adjusting
urvival by multivariate Cox regression analysis using ad-
anced age, previous stroke, poor left ventricular function,
eart failure, diabetes, peripheral vascular disease, and no
eft internal thoracic artery use, mild to moderate MR was
ot an independent predictor of long-term mortality. Be-
ause survival differences observed in the MR subgroup were
ully explained by other variables, operative repair of MR
ould have been unlikely to change survival. This long-term
eport of the follow-up of CABG patients presenting with
ild to moderate MR and treated with revascularization
lone provides an important framework to design prospec-
ive, randomized studies to definitively address this impor-
ant issue.
rosthetic valve performance. A prospective study com-
ared outcomes of the Starr Edwards and St. Jude prosthe-
es inserted in the aortic (267 patients) and mitral positions
122 patients) (18). Patients were randomized during the
perative procedure after the valve was excised and the
perating surgeon was at equipoise with the value of the two
rostheses. The specific valve was allocated by minimization
sing a computer program to stratify important clinical
haracteristics. Actuarial event-free survival did not differ
or either the mitral or aortic valve comparisons. Symptom
elief was similar at five years after surgery, and no signifi-
ant difference was found in complication rates during
ollow-up, except that eight patients with Starr Edwards
ortic valves developed infectious endocarditis, compared
ith only one patient with a St. Jude aortic valve. Left
entricular function had a marked effect on long-term durvival that overwhelmed the small, insignificant differ-
nces that might be related to the different prostheses used.
his study suggests that many of the touted benefits of
pecific cardiac valves discussed in observational studies
ight be of less significance or absent if cardiac valves were
ubjected to the rigor of randomized clinical trials.
rognosis in endocarditis. A retrospective observational
ohort study conducted from January 1990 to January 2000
t seven Connecticut hospitals derived a multivariate model
o predict death in 259 adults with left-sided native valve
ndocarditis, which was prospectively validated in a separate
ohort of 254 patients (19). The six-month mortality rate
sed as the modeling end point was 25% in the derivation
nd 26% in the validation samples. Five baseline features
ere independently associated with six-month mortality
nd, after validation, were used to derive a simple scoring
ystem to predict mortality for individual patients (Table 4).
he fact that underuse of surgery appeared to contribute
ndependently to mortality suggests that a lower threshold
or operation used prospectively would be likely to decrease
ortality. Until further studies examine the interaction
etween use of surgery and other prognostic variables to
efine information that might suggest the value of surgery is
onfined to specific subgroups, it is reasonable to consider
atients increasingly as surgical candidates as a function of
heir predicted mortality.
ptimal anticoagulation with mechanical heart valves.
meta-analysis from 35 studies, including 23,145 total
atients studied for 108,792 patient-years, suggests that the
ptimal intensity of vitamin K antagonists in patients with
echanical heart valves should range from an international
ormalized ratio of 3.0 to 4.5, with patients with aortic
alves managed at the lower side of this range and patients
ith mitral valves managed at the higher side of this range
20).
URGERY FOR CONGENITAL HEART DISEASE
europrotection during cardiopulmonary bypass in in-
ants. Neurodevelopment status was evaluated in 155 in-
ants with dextro-transposition of the great arteries, who by
andom assignment underwent either total circulatory arrest
r low-flow cardiopulmonary bypass for neuroprotection
able 4. Prediction of Six-Month Endocarditis Mortality
Parameter Points Description
ental status 0–4 4  Lethargy and disorientation
omorbidity 0–3 3  Charleston score 2
eart failure 0–3 3 Moderate-severe
reatment 0–5 5 Medical therapy only
icrobiology 0–8 0  Streptococcus viridans
6  Staphylococcus aureus
8  Other
otal points* 6 7–11 12–15 15
-month mortality 7% 19% 32% 69%
A mortality calculator was used to determine 6-month mortality from total points.uring an arterial switch operation (21). Treatment groups
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Year in Cardiovascular Surgery May 5, 2004:1706–14id not differ on most subsequent determinations of neuro-
ogic status, including IQ score, academic achievement,
emory, problem solving, and visual motor integration.
owever, children assigned to total circulatory arrest per-
ormed worse on tested motor function. Although the mean
cores on most outcomes were within normal limits, neuro-
evelopmental status in the cohort as a whole was below
xpectations in many dimensions. In a companion paper,
onparametric regression and piecewise linear models indi-
ated that neurodevelopmental outcomes were generally not
dversely affected, unless the duration of circulatory arrest
xceeded a threshold of 41 min (22). However, this thresh-
ld was not sufficiently discriminatory to be interpreted as a
niversally safe duration for total circulatory arrest.
nfluence of hemodilution on outcome of cardiopulmo-
ary bypass in infants. A single-center, randomized trial
sing two hemodilution protocols during hypothermic car-
iopulmonary bypass was conducted in 174 infants under-
oing cardiac surgery (23). The cardiopulmonary bypass
ump was configured to attain a hematocrit of 21.5 in the
ohort randomized to a low hematocrit and to 27.8 in the
ohort randomized to a high hematocrit. At age one year,
he lower hematocrit group had worse scores on the Psy-
homotor Development Index (81.9 15.7 vs. 89.7 14.7,
 0.008), demonstrating the practice of hemodilution to
low hematocrit level currently considered safe to be
ssociated with adverse developmental outcomes.
harmaceuticals for support of children undergoing
eart surgery. A placebo-controlled trial randomized pe-
iatric congenital heart surgery patients to placebo, low-
ose milrinone, or high-dose milrinone and evaluated the
omposite end point of death or development of low cardiac
utput syndrome at 36 h and 30 days (24). Among 238
reated patients, 25.9%, 17.5%, and 11.7% in the placebo,
ow-dose milrinone, and high-dose milrinone groups, re-
pectively, developed low cardiac output syndrome in the
rst 36 h after the operation. High-dose milrinone signifi-
antly reduced the risk of development of low cardiac output
yndrome, as compared with placebo (p  0.023). This trial
rovides evidence suggestive of a benefit in a patient group
hat has not been extensively studied. However, the results
ust be considered only suggestive, because clinicians who
ere blinded as to the drug could easily recognize children
eceiving placebo infusion by their blood pressure stability,
n contrast to the acute hypotension consistently induced by
ilrinone infusion. Moreover, only two deaths occurred,
nd both were associated with infusion of the study drug.
herefore, the trial only showed a change in the clinical
iagnosis of low cardiac output syndrome and not in actual
atient outcomes.
A double-blinded, randomized, placebo-controlled study
valuated the efficacy of aprotinin in attenuating hemostatic
nd inflammatory activation during cardiopulmonary bypass
n 60 patients weighing 10 kg (25). Secondary end points
ncluded the influence of aprotinin on reduction of blood
oss, blood transfusion requirement, adequacy of postoper- ltive oxygenation, and length of mechanical ventilation.
he 24-h chest tube drainage was 5.9 ml/kg less during the
rst 24 h after the operation in aprotinin-treated children.
lood transfusion beyond that used to prime the heart–lung
achine for all operations was required in 13% of aprotinin-
reated and 47% of placebo-administered children (p 
.05). Also, postoperative oxygenation was lower and time
n the ventilator was shorter in the aprotinin group. No side
ffects were attributed to aprotinin. High-dose aprotinin
ay be effective in attenuating hemostatic activation in
educing blood loss in pediatric cardiac surgery.
ulmonary embolism in adult Fontan patients. A group
f 30 adult Fontan outpatients without specific symptoms
nderwent ventilation-perfusion scans to detect pulmonary
mbolism (26). A positive scan, which confirmed pulmo-
ary embolism by pulmonary angiography, was present in 5
17%) of the 30 patients. No pulmonary emboli were
resent in the nine patients taking warfarin. A prospective
rial evaluating the importance of anticoagulation therapy in
dult Fontan patients appears warranted.
TATUS REPORT OF MAJOR ONGOING RANDOMIZED
LINICAL TRIALS IN CARDIAC SURGICAL PATIENTS
utcomes After Myocardial Revascularization: On and
ff Cardiopulmonary Bypass
PONSOR: Veterans Affairs Cooperative Study.
RINCIPAL INVESTIGATOR: Frederick L. Grover, MD
Frederick.Grover@uchsc.edu).
YPOTHESIS: In properly selected patients, 30-day and
-year mortality and morbidity are equivalent when CABG
s conducted with or without using cardiopulmonary bypass.
ECONDARY END POINTS: Angiographic graft status, com-
leteness of revascularization, recurrent ischemia, neuropsy-
hological status, quality of life, and resource use.
ESIGN: Randomization stratified by surgeon; urgent or
lective isolated CABG procedures; 2,200 patients random-
zed within four years; one-year follow-up.
EBRUARY 2004 STATUS: Total of 3,214 patients screened,
58 randomized; major exclusion: small, diffusely diseased
oronary arteries (35%); conversion rates: 9.9% for off- to
n-pump and 2.5% for on- to off-pump; outcomes of total
roup: death in 3.2%, perioperative myocardial infarction
.3%, return to the operating room for bleeding (48 h) 1.8%,
ardiac arrest 1.6%, repeat cardiac surgery 0.2%, stroke
.1%, sternal wound infection 1.4%, and renal failure 1.3%.
LINICAL SITES: Seventeen U.S. Veterans Affairs hospitals.
urgical Treatment for IschemiC Heart failure (STICH
rial)
PONSOR: National Institutes of Health, Bethesda, Mary-
and.
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jones060@mc.duke.edu).
YPOTHESES: 1) CABG combined with intensive medical
herapy (MED) improves long-term survival, compared
ith MED alone, in 2,000 patients with a left ventricular
jection fraction 35% and CAD amenable to CABG; 2)
urgical ventricular restoration (SVR) combined with
ABG and MED improves survival free of cardiac hospi-
alization, compared with CABG and MED without SVR.
ECONDARY END POINTS: Cardiac mortality and morbidity,
esource use, quality of life, noninvasive cardiac study predic-
ion of primary end points by myocardial ischemia and viabil-
ty, left ventricular size and function, neurohormonal and
ytokine levels, and genetic polymorphisms or mutations.
igure 4. Distribution of Surgical Treatment for IschemiC Heart failure
ypass grafting; CAD  coronary artery disease; EF  ejection fraction;
estoration.
able 5. Characteristics of STICH Patients as of
arch 1, 2004
Characteristics
Revascularization
Hypothesis
SVR
Hypothesis Total
atients enrolled 150 274 402
atients with data 120 225 327
nrolling sites 40 48 54
o angina 42% 23% 29%
eart failure class III 49% 49% 49%
VEF 25.6  6.4 26.2  6.4 26.0  6.5
SVI (ml/m2) 84.6  3.1 88.7  39.8 87.6  37.2
ata are presented as the number or percentage of subjects or as the mean value 
D.
ESVI  end-systolic volume index; LVEF  left ventricular ejection fraction;
TICH  Surgical Treatment for IschemiC Heart failure trial; SVR  surgical
entricular restoration.ESIGN: A total of 2,800 patients with a left ventricular
jection fraction35% and CAD amenable to CABG will be
tratified on the basis of MED eligibility (no left main stenosis
50% or angina class III by the Canadian Cardiovascular
ociety) and SVR eligibility (dominant anterior akinesia or
yskinesia amenable to SVR). The allocation of patients to
reatment within each stratum is illustrated in Figure 4.
atients eligible for either MED or CABG but not eligible for
he SVR procedure (stratum A) will be randomized in equal
roportions to MED or CABG. Patients eligible for all three
herapies (stratum B) will be randomized in equal proportions
o MED, CABG, or CABG plus SVR. Patients whose angina
r CAD severity makes them ineligible for MED but who are
ppropriate candidates for both CABG and SVR (stratum C)
ill be randomized in equal proportions to CABG or CABG
lus SVR. Use of patients in stratum B assigned to CABG, to
ddress both primary hypotheses, provides 3,000 end points
rom 2,800 enrolled patients.
EBRUARY 2004 STATUS: Table 5 demonstrates the charac-
eristics of 261 randomized patients.
LINICAL SITES: North American, European, Asian-Pacific,
nd South American sites added at a rate of five per month
ntil the goal of 100 enrolling sites was achieved. Enrollment
rojected for completion is December 2006 for the revascular-
zation hypothesis and April 2005 for the SVR hypothesis.
eprint requests and correspondence: Dr. Robert H. Jones, P.O.
ox 17969, Duke Clinical Research Institute, Durham, North
arolina 27715. E-mail: jones060@mc.duke.edu.
H) trial patients among randomization strata. CABG  coronary artery
left ventricular; MED  medical therapy; SVR  surgical ventricular(STIC
LV 
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